Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 2/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | FPR1 | P21462 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338594 | 0.91 | ASAH1 (0.34) | KMT2AGAANPC1RAB9AALDH1A1 | |
| SCHEMBL1336807 | 0.85 | ALDH1A1 (0.40) | KMT2AMEN1ATMCXCR3GAA | |
| SCHEMBL1338964 | 0.83 | GSK3B (0.41) | KMT2AMEN1ATMCXCR3GAA | |
| SCHEMBL1338400 | 0.82 | GABRA1 (0.37) | NPC1RAB9ASMN1; SMN2TSHRMAPT | |
| SCHEMBL1339292 | 0.81 | ALDH1A1 (0.34) | KMT2AMEN1GAAHPGDRAB9A | |
| SCHEMBL1338146 | 0.80 | MEN1 (0.39) | KMT2AMEN1ATMCXCR3GAA | |
| SCHEMBL3135467 | 0.79 | KMT2A (0.39) | KMT2AMEN1ATMCXCR3GAA | |
| SCHEMBL3135471 | 0.77 | KMT2A (0.36) | KMT2AMEN1ATMCXCR3GAA | |
| SCHEMBL1339068 | 0.76 | MEN1 (0.36) | KMT2AMEN1ATMCXCR3GAA | |
| SCHEMBL1339490 | 0.75 | CHRNA7 (0.40) | KMT2AMEN1GAANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063061-B2 | 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites | SANOFI-AVENTIS (FR) | 2011-11-22 | — | — | US | disclosed |
| EP-1940840-B1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-07-21 | — | — | EP | disclosed |
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1940840-A1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045758-A1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | CYP11B2, CYP11B1, CYP2D6 | KMT2A 2956/4885MEN1 2522/4885ATM 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.